Alaunos Therapeutics (TCRT) Cash from Financing Activities (2009 - 2023)

Alaunos Therapeutics has reported Cash from Financing Activities for 15 years, with the latest figure at -$12.0 million in Q2 2023.

• For the quarter ending Q2 2023, Cash from Financing Activities changed N/A year-over-year to -$12.0 million; the trailing twelve-month figure through Mar 2024 stood at -$12.0 million (down 5832.06% YoY), and the FY2025 full-year result was $3.3 million, changed N/A from the prior year.
• Cash from Financing Activities for Q2 2023 stood at -$12.0 million, down from -$6.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $101.7 million in Q1 2020, with the low at -$12.0 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged $11.7 million across 5 years, with a median of $230000.0 in 2019.
• The largest YoY upside for Cash from Financing Activities was 92218.52% in 2021 against a maximum downside of 146.5% in 2021.
• Alaunos Therapeutics' Cash from Financing Activities stood at $3.0 million in 2019, then slumped by 86.8% to $400000.0 in 2020, then tumbled by 146.5% to -$186000.0 in 2021, then jumped by 4655.91% to $8.5 million in 2022, then plunged by 241.37% to -$12.0 million in 2023.
• The last three Cash from Financing Activities figures came in at -$12.0 million (Q2 2023), -$6.2 million (Q1 2023), and $8.5 million (Q4 2022), per Business Quant data.